MX336435B - Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia. - Google Patents

Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.

Info

Publication number
MX336435B
MX336435B MX2008000178A MX2008000178A MX336435B MX 336435 B MX336435 B MX 336435B MX 2008000178 A MX2008000178 A MX 2008000178A MX 2008000178 A MX2008000178 A MX 2008000178A MX 336435 B MX336435 B MX 336435B
Authority
MX
Mexico
Prior art keywords
dementia
treatment
fatty acids
related conditions
polyunsaturated fatty
Prior art date
Application number
MX2008000178A
Other languages
English (en)
Other versions
MX2008000178A (es
Inventor
Lorie A Ellis
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of MX2008000178A publication Critical patent/MX2008000178A/es
Publication of MX336435B publication Critical patent/MX336435B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen composiciones y métodos para tratar o prevenir demencia y condiciones relacionadas con pre-demencia y/o síntomas o características de tales condiciones.
MX2008000178A 2005-07-08 2006-07-07 Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia. MX336435B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69791105P 2005-07-08 2005-07-08
US77914506P 2006-03-02 2006-03-02
PCT/US2006/026331 WO2007008586A2 (en) 2005-07-08 2006-07-07 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions

Publications (2)

Publication Number Publication Date
MX2008000178A MX2008000178A (es) 2008-04-07
MX336435B true MX336435B (es) 2016-01-19

Family

ID=37637739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008000178A MX336435B (es) 2005-07-08 2006-07-07 Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.

Country Status (12)

Country Link
US (3) US20070032548A1 (es)
EP (1) EP1904049B1 (es)
JP (4) JP2009502745A (es)
KR (5) KR20080027384A (es)
CN (2) CN103211807A (es)
AU (1) AU2006269405B2 (es)
BR (1) BRPI0613358A8 (es)
CA (1) CA2614473C (es)
ES (1) ES2617577T3 (es)
MX (1) MX336435B (es)
RU (1) RU2444356C2 (es)
WO (1) WO2007008586A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI120720B (fi) * 2006-06-16 2010-02-15 Neurofood Ab Oy Maitopohjaisia elintarvikkeita, jotka sisältävät keskushermoston lipidejä
US20080249058A1 (en) * 2007-04-05 2008-10-09 Erik Roberson Agents that reduce neuronal overexcitation
KR101409115B1 (ko) 2007-06-08 2014-06-17 엘지전자 주식회사 다중 안테나 시스템에서 가중치 정보 전송 방법
US20100331258A1 (en) * 2007-06-26 2010-12-30 N.V. Nutricia memory in subjects with mini-mental state examination of 24-26
WO2009082203A1 (en) 2007-12-20 2009-07-02 N.V. Nutricia Liquid nucleotides/nucleosides-containing product
WO2009002146A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
CN101802607A (zh) * 2007-07-26 2010-08-11 菲诺梅诺米发现公司 用于诊断、风险评价、和监测孤独症谱系病症的方法
US20090247860A1 (en) * 2007-10-25 2009-10-01 Research Foundation Of State University Of New York Spectral biomarker and algorithm for the identification and detection of neural stem and progenitor cells and their use in studying mammalian brains
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009058799A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
WO2009057994A1 (en) 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
ES2773928T5 (es) 2008-01-04 2023-06-28 Nestle Sa Composiciones que comprenden ácidos grasos insaturados y compuestos de liberación de óxido nítrico y uso de las mismas para la intensificación de las funciones cognitivas y relacionadas
WO2009158148A1 (en) * 2008-05-30 2009-12-30 The Trustees Of Columbia University In The City Of New York Methods for diagnosis and treatment of neurodegenerative diseases or disorders
JP2012516852A (ja) * 2009-02-02 2012-07-26 マーテック バイオサイエンシーズ コーポレーション 認知機能改善および心拍数低下のための方法
WO2010090025A1 (ja) * 2009-02-05 2010-08-12 パナソニック株式会社 撮像処理装置
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
KR20120014253A (ko) * 2009-04-14 2012-02-16 젠야쿠코교가부시키가이샤 프로-ａｄａｍ10 세크레타제 및/또는 베타 세크레타제 수치를 감소시키는 방법
WO2010118761A1 (en) * 2009-04-17 2010-10-21 Eolas Science Limited Compositions rich in omega-3 fatty acids with a low content in phytanic acid
WO2011006144A1 (en) 2009-07-10 2011-01-13 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
US20110082205A1 (en) 2009-10-01 2011-04-07 Panker Cynthia A Docosahexaenoic Acid Gel Caps
CA2777367A1 (en) * 2009-10-13 2011-04-21 Martek Biosciences Corporation Reducing the risk of pathological effects of traumatic brain injury
JP5934102B2 (ja) 2009-10-30 2016-06-15 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ誘導体による酸化ストレス障害の緩和
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
JP6106158B2 (ja) 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 酸化的網膜疾患
WO2012148926A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
CA2834343C (en) 2011-04-26 2021-10-12 Retrotope, Inc. Disorders implicating pufa oxidation
CA2834342C (en) 2011-04-26 2021-08-31 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
PL2579042T3 (pl) 2011-10-04 2014-12-31 Affiris Ag Sposób wykrywania przeciwciał swoistych wobec Aß w próbce biologicznej
MX356427B (es) * 2012-02-29 2018-05-29 Braun Melsungen Ag Emulsion que contiene hormona.
JP5986440B2 (ja) * 2012-07-05 2016-09-06 国立医薬品食品衛生研究所長 アルツハイマー病の発症を予測する方法
US20140203176A1 (en) * 2013-01-23 2014-07-24 Dow Agrosciences Llc Systems and methods for real-time sampling and analysis of biomolecules beneath the surface of biological tissue
CN103217463A (zh) * 2013-03-14 2013-07-24 中南大学 一种用于bace1抑制剂筛选的电化学方法
CN105163731B (zh) * 2013-07-10 2017-10-31 狮王株式会社 内服组合物
CN104368002B (zh) * 2014-10-17 2019-01-08 中国人民解放军军事医学科学院毒物药物研究所 用于治疗痴呆或认知功能障碍的联合用药物
WO2016112174A2 (en) * 2015-01-08 2016-07-14 The Trustees Of The University Of Pennsylvania Biomarkers of Sleep Deprivation and Cognitive Impairment
KR20170025977A (ko) * 2015-08-31 2017-03-08 재단법인차세대융합기술연구원 옥시리스 마리나로부터 분리된 신규 화합물
CA2997947A1 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3950649A1 (en) 2015-11-23 2022-02-09 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
KR20230161532A (ko) * 2015-11-24 2023-11-27 메사추세츠 인스티튜트 오브 테크놀로지 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법
US20190314442A1 (en) * 2016-02-22 2019-10-17 Newtricious B.V. Composition for the prevention or treatment of neurodegenerative diseases
CN106617064A (zh) * 2016-12-22 2017-05-10 徐晓飞 一种含姜黄素和ω‑3多不饱和脂肪酸的组合物及其应用
CN106666745A (zh) * 2016-12-22 2017-05-17 徐晓飞 一种含姜黄素和dha的组合物及应用
KR20190121782A (ko) * 2017-03-06 2019-10-28 준 리우 Aβ-유발 손상에 대한 억제 또는 경감제
US11065288B2 (en) 2017-09-29 2021-07-20 Kinjirushi Co., Ltd. Neuron activator
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
EP4107163A4 (en) 2020-02-21 2024-06-19 Retrotope, Inc. PROCESS FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES
KR102466479B1 (ko) 2020-03-30 2022-11-15 주식회사 뷰브레인헬스케어 타우 단백질 축적 예측 장치 및 이를 이용한 타우 단백질 축적 예측 방법
CN114680336A (zh) * 2020-12-30 2022-07-01 云南汉盟制药有限公司 一种含火麻仁不饱和脂肪酸的滴剂及其制备方法
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
CN112798727B (zh) * 2021-04-09 2021-07-06 宝枫生物科技（北京）有限公司 用于诊断脑白质病变的生物标志物f7及其应用
US20230333087A1 (en) * 2022-02-11 2023-10-19 Biojiva Llc Methods for monitoring patient response to treatment of retinal oxidative diseases

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5408326A (en) * 1993-04-28 1995-04-18 Shell Oil Company Dual-wavelength absorption detector adapted for continuous-flow detection
US5403826A (en) * 1993-05-28 1995-04-04 Abbott Laboratories Nutritional product for persons infected with human immunodeficiency virus
ATE181745T1 (de) 1994-08-16 1999-07-15 Frische Gmbh Verfahren zur gewinnung von nicht wasserlöslichen, nativen produkten aus nativen stoffgemengen mit hilfe der zentrifugalkraft
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
EP0935667B1 (en) * 1996-07-23 2006-12-06 Nagase Chemtex Corporation Process for preparing docosahexaenoic acid and docosapentaenoic acid
TR199900786T2 (xx) * 1996-10-11 1999-07-21 Scotia Holdings Plc Eykoza penta enoik asit ve/veya stearidonik asit i�eren farmas�tik terkipler.
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
KR100504324B1 (ko) * 1999-03-04 2005-07-28 산토리 가부시키가이샤 도코사펜타엔산 함유물질의 이용
CA2311974A1 (en) * 1999-06-28 2000-12-28 Nisshin Flour Milling Co., Ltd. Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
WO2001051598A1 (en) * 2000-01-11 2001-07-19 Monsanto Technology Llc Process for making an enriched mixture of polyunsaturated fatty acid esters
DE60140352D1 (de) 2000-04-12 2009-12-17 Gea Westfalia Separator Gmbh Verfahren zur fraktionierung von öl- und polar lipid-enthaltenden rohstoffen unter verwendung von alkohol und zentrifugation
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
JP4629834B2 (ja) * 2000-05-12 2011-02-09 備前化成株式会社 神経細胞賦活剤およびその利用
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
EP2283838A3 (en) * 2002-09-27 2011-04-20 Martek Biosciences Corporation Docosahexaenoic acid for treating subclinical inflammation
EP1558237A4 (en) * 2002-09-27 2007-01-17 Martek Biosciences Corp IMPROVED GLYCEMIC REGULATION IN PREDIABETE AND / OR DIABETES TYPE II USING DOCOSAHEXAENOIC ACID
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
JP2007524674A (ja) * 2004-01-19 2007-08-30 マーテック・バイオサイエンシーズ・コーポレーション リーリン欠損症または機能障害およびそれに関連する方法
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
US7884131B2 (en) * 2004-11-19 2011-02-08 Martek Biosciences, Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
DE102005003625A1 (de) * 2005-01-26 2006-07-27 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Verfahren zur Herstellung einer DHA-haltigen Fettsäure-Zusammensetzung
US20060270739A1 (en) * 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
CA2607247C (en) * 2005-05-04 2015-10-06 Pronova Biopharma Norge As .alpha.-substituted dha derivatives
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
PL1888081T3 (pl) * 2005-05-23 2017-07-31 Massachusetts Institute Of Technology Kompozycje zawierające PUFA i sposoby ich zastosowania
US20070042953A1 (en) * 2005-08-16 2007-02-22 Bazan Nicolas G Antiepileptogenic complex of albumin with docosahexaenoate
RU2400102C2 (ru) * 2005-08-26 2010-09-27 Нестек С.А. Композиция для лечения, замедления или предотвращения у животного слабоумия, старения мозга, когнитивного нарушения, инсульта или болезни альцгеймера и ее применение (варианты)
AU2008269989B2 (en) * 2007-06-29 2014-02-27 Dsm Ip Assets B.V. Production and purification of esters of polyunsaturated fatty acids

Also Published As

Publication number Publication date
CN101262863A (zh) 2008-09-10
WO2007008586A3 (en) 2007-04-12
US20150119464A1 (en) 2015-04-30
CN101262863B (zh) 2016-08-31
KR20160116351A (ko) 2016-10-07
EP1904049A4 (en) 2012-08-01
CN103211807A (zh) 2013-07-24
KR20180026556A (ko) 2018-03-12
BRPI0613358A2 (pt) 2011-01-04
EP1904049B1 (en) 2016-12-07
KR20190014122A (ko) 2019-02-11
KR101965124B1 (ko) 2019-04-02
US20110218242A1 (en) 2011-09-08
JP2015147775A (ja) 2015-08-20
EP1904049A2 (en) 2008-04-02
CA2614473C (en) 2016-05-03
WO2007008586A2 (en) 2007-01-18
CA2614473A1 (en) 2007-01-18
JP2013056900A (ja) 2013-03-28
RU2008104697A (ru) 2009-08-20
KR20080027384A (ko) 2008-03-26
KR20130101596A (ko) 2013-09-13
BRPI0613358A8 (pt) 2017-12-26
JP2018021078A (ja) 2018-02-08
RU2444356C2 (ru) 2012-03-10
MX2008000178A (es) 2008-04-07
JP2009502745A (ja) 2009-01-29
AU2006269405B2 (en) 2013-01-17
ES2617577T3 (es) 2017-06-19
US20070032548A1 (en) 2007-02-08
KR101870626B1 (ko) 2018-06-26
AU2006269405A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
MX2008000178A (es) Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2007092622A3 (en) Compositions and methods for treating bone
MX342128B (es) Compuestos farmaceuticos.
NO20070561L (no) Sammensetninger og fremgangsmater for a behandle oyesykdommer og tilstander.
MX338235B (es) Microorganismos eucarioticos para producir lipidos y antioxidantes.
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2008011872A (es) Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
SG10201805844QA (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
MX2010009456A (es) Composicion detergente que comprende lipasa.
UA96442C2 (ru) Fad-2 мутанты и растения с высоким содержанием олеиновой кислоты
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
HK1106534A1 (en) Proteasome inhibitors and methods of using the same
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
AU2010306870A8 (en) Reducing the risk of pathological effects of traumatic brain injury
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
IN2015DN03331A (es)
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2011041680A3 (en) Compositions and methods of prophylaxis for contact dermatitis
WO2007136857A3 (en) Hox compositions and methods